Anastasia Gennadievna Samoilova - Infectious Diseases

Author Information

Dr. Anastasia Gennadievna Samoilova is a prominent researcher affiliated with the Federal State Budgetary Institution "National Medical Research Center of Phthisiopulmonology and Infectious Diseases" of the Ministry of Health of the Russian Federation, located in Moscow. Her work primarily focuses on infectious diseases, particularly tuberculosis and COVID-19, encompassing studies on drug resistance, treatment efficacy, and pathogen detection.

Research Contributions

Dr. Samoilova has made significant contributions to the field of infectious diseases. In 2022, she co-authored a prospective study on SARS-CoV-2-specific T cells and antibodies in COVID-19 protection. She has also extensively studied drug-resistant tuberculosis, examining the toxicity of treatment regimens and the effectiveness of broncho-alveolar lavage for pathogen detection in children. Her research includes evaluating the efficacy and safety of switching to dual therapy in HIV treatment and identifying predictors of severe COVID-19 in hospitalized patients. Dr. Samoilova's work with next-generation sequencing to detect Mycobacterium tuberculosis (MTB) resistance and her analysis of drug susceptibility test results highlight her comprehensive approach to understanding and combating infectious diseases.

Aliases

Anastasia Samoilova, A.g. Samoilova, Anastasia G Samoilova, Anastasia Gennadievna Samoilova, A. G. Samoilova, A G Samo\u012dlova, Anastasia G. Samoilova

Publication and Citation Metrics

Metric	Value
Citation Count	116
H-Index	4
Paper Count	34

Publications:

SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study.

DOI: 10.1093/cid/ciac278

Year: 2022

Toxicity of treatment regimens for drugresistant tuberculosis.

DOI: 10.37489/0235-2990-2021-66-11-12-25-30

Year: 2022

Switching to dual therapy after 24 weeks of the triple therapy of HIV infection: efficacy and safety

DOI: 10.33029/2305-3496-2021-10-4-66-75

Year: 2021

Predictors of severe COVID-19 disease in the inpatient cohort, Russian Federation

DOI: 10.1183/13993003.congress-2021.pa3806

Year: 2021

The effectiveness of broncho-alveolar lavage for the pathogen detection in children with pulmonary tuberculosis

DOI: 10.1183/13993003.congress-2021.oa4206

Year: 2021

Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study.

DOI: 10.4081/monaldi.2021.1678

Year: 2021

Beta-lactam antibiotics as reserve medications for the treatment of drug-resistant tuberculosis

DOI: 10.37489/0235-2990-2021-66-5-6-78-85

Year: 2021

Comparative analysis of M. tuberculosis drug susceptibility tests results in new multidrug-resistant tuberculosis cases and their confirmed contacts

DOI: 10.1183/13993003.congress-2020.1606

Year: 2020

Application of next-generation sequencing to detect MTB resistance to first- and second-line anti-TB drugs

DOI: 10.1183/13993003.congress-2020.1605

Year: 2020

Induction of M. tuberculosis (MTB) drug resistance (DR) mutations in HIV-infected hosts and pathways of further spread of the evolutionary successful drug-resistant MTB clonal lines

DOI: 10.1183/13993003.congress-2020.1596

Year: 2020

How Do Pathogens Invade Hosts?

How Does a PCR Test Work?

What are the Challenges with ACTs?

What diseases does it cause?

What are the guidelines for food safety?

What are the Symptoms of HSV?

What is Hygiene?

What are the Phases of the Inflammatory Response?

What Are the Symptoms of These Diseases?

How Are Infectious Diseases Transmitted?

Partnered Content Networks

Relevant Topics